Bifunctional stapled polypeptides and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
A61K-038/16
A61P-035/00
C07K-014/00
C07K-001/107
C40B-030/04
A61K-047/48
C07K-014/47
C07K-014/435
C12N-009/00
C07K-001/113
출원번호
US-0383881
(2010-07-13)
등록번호
US-9163330
(2015-10-20)
국제출원번호
PCT/US2010/001952
(2010-07-13)
§371/§102 date
20120706
(20120706)
국제공개번호
WO2011/008260
(2011-01-20)
발명자
/ 주소
Verdine, Gregory L.
Grossmann, Tom N.
Moellering, Raymond E.
Yeh, Tsung-Han Johannes
Liang, Yue Rebecca Yue
Oak, Youbean
출원인 / 주소
President and Fellows of Harvard College
대리인 / 주소
Wolf, Greenfield & Sacks, P.C.
인용정보
피인용 횟수 :
17인용 특허 :
70
초록▼
The invention relates to bifunctional stapled or stitched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or
The invention relates to bifunctional stapled or stitched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stitched peptides that bind to an effector biomolecule through the effector domain and bind to a target biomolecule through the targeting domain. Polypeptides and/or polypeptide complexes that are tethered by the bifunctional stapled or stitched peptides of the invention, where the effector polypeptide bound to the effector domain of the bifunctional stapled or stitched peptide modifies or alters the target polypeptide bound to the targeting domain of the bifunctional peptide. Uses of the inventive bifunctional stapled or stitched peptides including methods for treatment of disease (e.g., cancer, inflammatory diseases) are also provided.
대표청구항▼
1. A bifunctional peptide comprising: a targeting domain;a linker moiety; andan effector domain; wherein the linker moiety links the targeting domain to the effector domain, andboth the targeting domain and the effector domain are independently stapled or stitched peptides. 2. The peptide of claim 1
1. A bifunctional peptide comprising: a targeting domain;a linker moiety; andan effector domain; wherein the linker moiety links the targeting domain to the effector domain, andboth the targeting domain and the effector domain are independently stapled or stitched peptides. 2. The peptide of claim 1, wherein both the targeting domain and the effector domain are stapled. 3. The peptide of claim 1, wherein at least one of the targeting domain and the effector domain comprises a sub-domain of Formula (I): wherein in the sub-domain of Formula (I) each instance of L1 and L2 is, independently, a bond; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkynylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkynylene; a substituted or unsubstituted arylene; a substituted or unsubstituted heteroarylene; or a substituted or unsubstituted acylene;each instance of Ra is, independently, hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a cyclic or acyclic, substituted or unsubstituted acyl; or an amino protecting group;each instance of Rb is, independently, an amino acid side chain; hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a cyclic or acyclic, substituted or unsubstituted acyl; a substituted or unsubstituted hydroxyl; a substituted or unsubstituted thiol; a substituted or unsubstituted amino; cyano; isocyano; halo; or nitro;each instance of Re is, independently, a bond to the linker moiety; —RE; —ORE; —N(RE)2; or —SRE;each instance of RE is, independently, hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a substituted or unsubstituted acyl; a resin; a hydroxyl protecting group; an amino protecting group; a thiol protecting group; or two RE groups of —N(RE)2 together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring;each instance of Rf is, independently, a bond to the linker moiety; hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a substituted or unsubstituted acyl; a resin; an amino protecting group; a label optionally joined by a tether, wherein the tether is selected from cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkynylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkynylene; substituted or unsubstituted arylene; substituted or unsubstituted heteroarylene; or substituted or unsubstituted acylene; or Rf and Ra of a terminal amino acid together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring;each instance of RLL is, independently, a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a substituted or unsubstituted acyl; a substituted or unsubstituted hydroxyl; a substituted or unsubstituted thiol; a substituted or unsubstituted amino; azido; cyano; isocyano; halo; or nitro; or two adjacent RLL groups are joined to form a substituted or unsubstituted 5- to 8-membered cycloaliphatic ring; substituted or unsubstituted 5- to 8-membered cycloheteroaliphatic ring; substituted or unsubstituted aryl ring; or substituted or unsubstituted heteroaryl ring;each instance of XAA is, independently, a natural or unnatural amino acid;each instance of z is, independently, an integer from 2 to 6;each instance of j is, independently, an integer from 1 to 10;each instance of s and t is, independently, an integer from 0 and 100;each instance of q is, independently, an integer from 0 to 2; and corresponds to a single or double bond. 4. The peptide of claim 3, wherein is a double bond in the sub-domain of Formula (I). 5. The peptide of claim 1, wherein at least one of the targeting domain and the effector domain comprises a sub-domain of Formula (II): wherein each instance of K, L1, L2, and M, is, independently, a bond; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkynylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkynylene; a substituted or unsubstituted arylene; a substituted or unsubstituted heteroarylene; or a substituted or unsubstituted acylene;each instance of Ra is, independently, hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a cyclic or acyclic, substituted or unsubstituted acyl; or an amino protecting group;each instance of Rb is, independently, an amino acid side chain; hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; cyclic or acyclic, substituted or unsubstituted acyl; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; cyano; isocyano; halo; or nitro;each instance of Re is, independently, a bond to the linker moiety; —RE; —ORE; —N(RE)2; or —SRE; wherein each instance of RE is, independently, hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted acyl; a resin; a hydroxyl, amino, or thiol protecting group; or two RE groups of —N(RE)2 together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring;each instance of Rf is, independently, a bond to the linker moiety; hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted acyl; a resin; an amino protecting group; a label optionally joined by a tether, wherein the tether is selected from cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkynylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkynylene; substituted or unsubstituted arylene; substituted or unsubstituted heteroarylene; or substituted or unsubstituted acylene; or Rf and Ra together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring;each instance of RKL, RLL, and RLM, is, independently, cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted acyl; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; azido; cyano; isocyano; halo; nitro; or two adjacent RKL groups are joined to form a substituted or unsubstituted 5- to 8-membered cycloaliphatic ring; substituted or unsubstituted 5- to 8-membered cycloheteroaliphatic ring; substituted or unsubstituted aryl ring; or substituted or unsubstituted heteroaryl ring; or two adjacent RLL groups are joined to form a substituted or unsubstituted 5- to 8-membered cycloaliphatic ring; substituted or unsubstituted 5- to 8-membered cycloheteroaliphatic ring; substituted or unsubstituted aryl ring; or substituted or unsubstituted heteroaryl ring; or two adjacent RLM groups are joined to form a substituted or unsubstituted 5- to 8-membered cycloaliphatic ring; substituted or unsubstituted 5- to 8-membered cycloheteroaliphatic ring; substituted or unsubstituted aryl ring; or substituted or unsubstituted heteroaryl ring;each instance of XAA is, independently, a natural or unnatural amino acid;each instance of y and z is, independently, an integer from 2 to 6;each instance of j is, independently, an integer from 1 to 10;each instance of p is, independently, an integer from 0 to 10;each instance of s and t is, independently, an integer from 0 and 100;each instance of u, v, and q, is, independently, an integer from 0 to 2; and corresponds to a single or double bond. 6. The peptide of claim 5, wherein is a double bond in the sub-domain of Formula (II). 7. The peptide of claim 1, wherein the linker moiety is an aminohexanoic acid monomer or a polymer of aminohexanoic acid. 8. The peptide of claim 1, wherein the linker moiety is an aminohexanoic acid monomer. 9. The peptide of claim 1, wherein the linker moiety is a polymer of aminohexanoic acid. 10. The peptide of claim 1, wherein the targeting domain binds β-catenin, Myc, Ras, or hypoxia-inducible factor. 11. The peptide of claim 1, wherein the targeting domain is a ligand for β-catenin. 12. The peptide of claim 11, wherein the targeting domain is a stapled Bcl9 or a derivative thereof, or a stapled Tcf-4 or a derivative thereof. 13. The peptide of claim 12, wherein the targeting domain is a stapled Bcl9 or a derivative thereof. 14. The peptide of claim 12, wherein the targeting domain is a stapled Tcf-4 or a derivative thereof. 15. The peptide of claim 1, wherein the targeting domain is a ligand for Myc. 16. The peptide of claim 15, wherein the targeting domain is a stapled Max or a derivative thereof, a stapled Mad or a derivative thereof, or a stapled Mxi or a derivative thereof. 17. The peptide of claim 1, wherein the targeting domain is a ligand for Ras or hypoxia-inducible factor. 18. The peptide of claim 1, wherein the effector domain modulates the activity of an enzyme. 19. The peptide of claim 18, wherein the enzyme is a ubiquitinating enzyme, a glycosylating enzyme, a histone deacetylase, a histone acetyl transferase, a phosphorylating enzyme, or a dephosphorylating enzyme. 20. The peptide of claim 1, wherein the effector domain is a ligand for a ubiquitinating enzyme. 21. The peptide of claim 20, wherein the ubiquitinating enzyme is an E3 ubiquitin ligase. 22. The peptide of claim 21, wherein the E3 ubiquitin ligase is hDM2, MDM2, ubiquitin protein ligase E3A, a RING finger domain, or an SCF E3 ligase complex. 23. The peptide of claim 22, wherein the E3 ubiquitin ligase is hDM2, and the ligand for hDM2 is a stapled p53. 24. The peptide of claim 1, wherein the effector domain is a ligand for a glycosylating enzyme, a histone deacetylase, a histone acetyl transferase, a kinase, or a phosphatase. 25. The peptide of claim 1, having the Formula (III): wherein is a stapled Tcf4 or a derivative thereof; is a stapled alpha-helix of p53 or a derivative thereof; is a linker moiety;Re is a bond to the linker moiety, —RE, —ORE, —N(RE)2, or —SRE;each RE is, independently, hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted acyl; a resin; a hydroxyl, amino, or thiol protecting group; or two RE groups of —N(RE)2 together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring; andRf is a bond to the linker moiety; hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a substituted or unsubstituted acyl; a resin; an amino protecting group; or a label optionally joined by a tether, wherein the tether is selected from cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkynylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkynylene; substituted or unsubstituted arylene; substituted or unsubstituted heteroarylene; or substituted or unsubstituted acylene. 26. The peptide of claim 25, wherein comprises the sequence QSQQTFR8NLWRLLS5QN (SEQ ID NO: 29). 27. The peptide of claim 25, wherein comprises the sequence DELISFKDEGEQE(βAla)2ERDLS5DVKS5SLVN (SEQ ID NO: 30) or DELISFKDEGEQE(βAla)2ER8DLADVKS5SLVN (SEQ ID NO: 31), wherein βAla is β-alanine. 28. The peptide of claim 25, wherein is a linker comprising 2, 3, or 4 aminohexanoic acid residues. 29. The peptide of claim 25, having the sequence DELISFKDEGEQE(βAla)2ERDLS5DVKS5SLVN(Ahx)nQSQQTFR8NLWRLLS5QN (SEQ ID NO: 15) or DELISFKDEGEQE(βAla)2ER8DLADVKS5SLVN(Ahx)nQSQQTFR8NLWRLLS5QN (SEQ ID NO: 16), wherein βAla is β-alanine, Ahx is aminohexanoic acid, and n is 2, 3, or 4. 30. The peptide of claim 1, having the Formula (IV): wherein is a stapled Tcf4 or a derivative thereof; is a stapled alpha-helix of p53 or a derivative thereof; is a linker moiety;Re is a bond to the linker moiety, —RE, —ORE, —N(RE)2, or —SRE;each RE is, independently, hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted acyl; a resin; a hydroxyl, amino, or thiol protecting group; or two RE groups of —N(RE)2 together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring; andRf is a bond to the linker moiety; hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a substituted or unsubstituted acyl; a resin; an amino protecting group; or a label optionally joined by a tether, wherein the tether is selected from cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkynylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkynylene; substituted or unsubstituted arylene; substituted or unsubstituted heteroarylene; or substituted or unsubstituted acylene. 31. The peptide of claim 30, wherein comprises the sequence QSQQTFR8NLWRLLS5QN (SEQ ID NO: 29). 32. The peptide of claim 30, wherein comprises the sequence DELISFKDEGEQE(βAla)2ERDLS5DVKS5SLVN (SEQ ID NO: 30) or DELISFKDEGEQE(βAla)2ER8DLADVKS5SLVN (SEQ ID NO: 31), wherein βAla is β-alanine. 33. The peptide of claim 30, wherein is a linker comprising 2, 3, or 4 aminohexanoic acid residues. 34. The peptide of claim 30, having the sequence QSQQTFR8NLWRLLS5QN(Ahx)nDELISFKDEGEQE(βAla)2ERDLS5DVKS5SLVN (SEQ ID NO: 13) or QSQQTFR8NLWRLLS5QN(Ahx)nDELISFKDEGEQE(βAla)2ER8DLADVKS5SLVN (SEQ ID NO: 14), wherein βAla is β-alanine, Ahx is aminohexanoic acid, and n is 2, 3, or 4. 35. The peptide of claim 1, having the Formula (V): wherein is a stapled Bcl9 or a derivative thereof; is a stapled alpha-helix of p53 or a derivative thereof; is a linker moiety;Re is a bond to the linker moiety, —RE, —ORE, —N(RE)2, or —SRE;each RE is, independently, hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted acyl; a resin; a hydroxyl, amino, or thiol protecting group; or two RE groups of —N(RE)2 together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring; andRf is a bond to the linker moiety; hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a substituted or unsubstituted acyl; a resin; an amino protecting group; or a label optionally joined by a tether, wherein the tether is selected from cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkynylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkynylene; substituted or unsubstituted arylene; substituted or unsubstituted heteroarylene; or substituted or unsubstituted acylene. 36. The peptide of claim 35, wherein comprises the sequence QSQQTFR8NLWRLLS5QN (SEQ ID NO: 29). 37. The peptide of claim 35, wherein is a linker comprising 2, 3, or 4 aminohexanoic acid residues. 38. The peptide of claim 35, wherein comprises the sequence SQEQLR8HRERSLS5TLRDIQRMLF (SEQ ID NO: 32), SQEQLEHRERSLS5TLRS5IQRMLF (SEQ ID NO: 33), or SQEQLEHRS5RSLS5TLRDIQRMLF (SEQ ID NO: 34). 39. The peptide of claim 35, having the sequence SQEQLR8HRERSLS5TLRDIQRMLF(Ahx)nQSQQTFR8NLWRLLS5QN (SEQ ID NO:4), SQEQLEHRERSLS5TLRS5IQRMLF(Ahx)nQSQQTFR8NLWRLLS5QN (SEQ ID NO: 5), or SQEQLEHRS5RSLS5TLRDIQRMLF(Ahx)nQSQQTFR8NLWRLLS5QN (SEQ ID NO: 6), wherein Ahx is aminohexanoic acid, and n is 2, 3, or 4. 40. The peptide of claim 1, having the Formula (VI): wherein is a stapled Bcl9 or a derivative thereof; is a stapled alpha-helix of p53 or a derivative thereof; is a linker moiety;Re is a bond to the linker moiety, —RE, —ORE, —N(RE)2, or —SRE;each RE is, independently, hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted acyl; a resin; a hydroxyl, amino, or thiol protecting group; or two RE groups of —N(RE)2 together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring; andRf is a bond to the linker moiety; hydrogen; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; a cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; a substituted or unsubstituted heteroaryl; a substituted or unsubstituted acyl; a resin; an amino protecting group; or a label optionally joined by a tether, wherein the tether is selected from cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkynylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkynylene; substituted or unsubstituted arylene; substituted or unsubstituted heteroarylene; or substituted or unsubstituted acylene. 41. The peptide of claim 40, having the sequence: (SEQ ID NO: 1)QSQQTFR8NLWRLLS5QN(Ahx)nSQEQLR8HRERSLS5TLRDIQRMLF,(SEQ ID NO: 2)QSQQTFR8NLWRLLS5QN(Ahx)nSQEQLEHRERSLS5TLRS5IQRMLF,or(SEQ ID NO: 3)QSQQTFR8NLWRLLS5QN(Ahx)nSQEQLEHRS5RSLS5TLRDIQRMLF; wherein Ahx is aminohexanoic acid, and n is 2, 3, or 4. 42. A composition comprising the peptide of claim 1, and an excipient. 43. A method of treating a cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of the peptide of claim 1, to the subject in need thereof; wherein the cancer is selected from the group consisting of carcinoma, sarcoma, metastatic cancer, breast cancer, ovarian cancer, colon cancer, lung cancer, fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, gastric cancer, esophageal cancer, rectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, uterine cancer, cancer of the head and neck, skin cancer, brain cancer, squamous cell carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular cancer, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, Kaposi's sarcoma, and any combination thereof. 44. The peptide of claim 1, wherein the targeting domain is a ligand for Sin3. 45. The peptide of claim 44, wherein the ligand for Sin3 is a stapled Sin3 interacting domain (SID) of Mad1 or a derivative thereof. 46. The peptide of claim 45, wherein the stapled Sin3 interacting domain (SID) of Mad1 comprises the sequence: VRMNIQMLLEAADYLERREREAEH;(SEQ ID NO: 85)orVRMNIQMLLEAADYLERRER.(SEQ ID NO: 86) 47. The peptide of claim 45, wherein the stapled Sin3 interacting domain (SID) of Mad1 comprises the sequence: βAla-VRRRI S5MLLS5AANYLER;(SEQ ID NO: 88)orβAla-VRRRIQMLLEAANKS5ERRS5R;(SEQ ID NO: 91) wherein the non-natural amino acids S5 are cross-linked. 48. The peptide of claim 1, wherein the effector domain is a stapled, truncated MLL. 49. The peptide of claim 1, wherein the effector domain is a stapled, truncated cMyb. 50. The peptide of claim 48, wherein the effector domain comprises the sequence: ILP*DIM*FVLKNT,(SEQ ID NO: 81)ILP*RIM*FVLKNT,(SEQ ID NO: 82)ILPSDIM*FVL*NT,(SEQ ID NO: 83)orILPSRIM*FVL*NT;(SEQ ID NO: 84) wherein “*” are non-natural amino acids that are cross-linked. 51. The peptide of claim 49, wherein the effector domain comprises the sequence: K*KRI*ELELLLMSTENELKG,(SEQ ID NO: 73)K*KRI*RLELLLMSTENELKG,(SEQ ID NO: 74)KE*RIK*LELLLMSTENELKG,(SEQ ID NO: 75)KR*RIK*LELLLMSTENELKG,(SEQ ID NO: 76)KE*RIKELE*LLMSTENELKG,(SEQ ID NO: 77)KE*RIKRLE*LLMSTENELKG,(SEQ ID NO: 78)KR*RIKELE*LLMSTENELKG,(SEQ ID NO: 79)orKEKRIKELELLLMSTE*ELK*;(SEQ ID NO: 80) wherein “*” are non-natural amino acids that are cross-linked. 52. The peptide of claim 3, wherein Ra is hydrogen. 53. The peptide of claim 3, wherein Rb is hydrogen. 54. The peptide of claim 3, wherein Rb is alkyl. 55. The peptide of claim 3, wherein Rb is methyl. 56. The peptide of claim 1, having the sequence QSQQTFR8NLWRLLS5QN(Ahx)2NPES5ILDS5HVQRVMR (SEQ ID NO: 26), wherein Ahx is aminohexanoic acid.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (70)
Goueli, Said A., Alkyl peptide amides and applications.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Braisted Andrew C. ; Judice J. Kevin ; McDowell Robert S. ; Phelan J. Christopher ; Starovasnik Melissa A. ; Wells James A., Constrained helical peptides and methods of making same.
Bohme Ekkehard H. (Cincinnati OH) Gerhart Fritz (Kehl Leutesheim DEX) Higgins William (Strasbourg FRX), Derivatives of 2,6-diamino-3-haloheptanedioic acid.
Lane,David Philip; B철ttger,Volker; B철ttger,Angelika; Picksley,Steven Michael; Hochkeppel,Heinz Kurt; Garcia Echeverria,Carlos; Ch챔ne,Patrick; Furet,Pascal, Inhibitors of the interaction between P53 and MDM2.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Grubbs Robert H. ; Miller Scott J. ; Blackwell Helen E., Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.